Breaking tolerance in cancer immunotherapy: time to ACT.

@article{Overwijk2005BreakingTI,
  title={Breaking tolerance in cancer immunotherapy: time to ACT.},
  author={Willem W. Overwijk},
  journal={Current opinion in immunology},
  year={2005},
  volume={17 2},
  pages={
          187-94
        }
}
  • W. Overwijk
  • Published 1 April 2005
  • Biology, Medicine
  • Current opinion in immunology

Tables from this paper

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.
TLDR
Progress in all these areas is continuing based on clear evidence that cancer immunotherapy designed to overcome immune tolerance can be useful for a growing number of patients with cancer.
Developments in anticancer vaccination: budding new adjuvants
TLDR
The purpose of this review is to summarize the latest discoveries of TLR-synthetic agonists with adjuvant potential in anti-cancer vaccination.
Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention
TLDR
Research over the past decade has brought to light several mechanisms used by melanomas and other tumors to suppress tumor-specific immune responses, including the presence of regulatory immune cells within the tumor microenvironment and draining lymph nodes that serve to shut down effector T-cell function.
Strategies of Tumor Immune Evasion
TLDR
Both host- and tumor-related mechanisms can lead to a failure to mount a proper anti-tumor-specific immune response, and these are frequently key factors in limiting the success of cancer immunotherapy.
Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms
TLDR
This review will focus on the major regulatory cell subtypes, including CD4+CD25+ T-regulatory cells, type 1 regulatory T cells, natural killer T Cells, and immature myeloid cells, which have shown a role in tumor progression, although the mechanisms by which they act to suppress immunity remain largely undefined.
Targeting cancer associated fibroblasts for cancer immunotherapy
TLDR
This review summarized the progress of the emerging field of FAP-targeted cancer immunotherapy, where a dendritic cell (DC) vaccine expressing FAP has been generated.
Dendritic cell vaccine strategies for renal cell carcinoma
  • D. Schendel
  • Biology, Medicine
    Expert opinion on biological therapy
  • 2007
TLDR
Improved clinical efficacy may also be achieved using DCs that secrete biologically active IL-12, which fosters innate immunity and polarizes T helper type 1 responses that contribute to optimal antitumor immunity.
Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.
TLDR
The data presented in this review support the clinical combination of multi-targeted antiangiogenic TKIs, including but not limited to cabozant inib, sunitinib, and sorafenib, as well as to other anti-VEGF antibody bevacizumab with cancer vaccines for improved treatment of solid tumors.
TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation1
TLDR
The value of TCR gene transfer to target otherwise nonimmunogenic tumor-associated self-Ags provided that adoptive transfer occurs under conditions that allow in vivo expansion of the TCR-modified T cells is demonstrated.
Reshaping the Immunosuppressive Tumor Microenvironment: The Fusion Protein Strategy
TLDR
Evaluated fusion proteins coupled with appropriate delivery approaches represent a promising strategy for the conversion of the environment from immunosuppressive to immune active for effective cancer immunotherapies.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Tumors as elusive targets of T-cell-based active immunotherapy.
Cancer Immunotherapy: A Treatment for the Masses
TLDR
The challenge for immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor responses.
Tuning tumor-specific T-cell activation: a matter of costimulation?
The future of interleukin-2: enhancing therapeutic anticancer vaccines.
TLDR
The addition of recombinant and synthetic cancer vaccines to a regimen of IL-2 can result in improved antitumor responses in both animal models and melanoma patients, and may enhance the therapeutic effectiveness of anticancer vaccines.
Vaccines: Spinning molecular immunology into successful immunotherapy
TLDR
Some of the most promising molecular and cellular targets for immunotherapy are reviewed and approaches that use these targets to amplify immune responses and potentially break antigen-specific tolerance are discussed, providing a blueprint for the development of successful immunotherapy over the next decade.
Cancer immunotherapy: moving beyond current vaccines
TLDR
Results in cancer vaccine trials are considered and alternate strategies that mediate cancer regression in preclinical and clinical models are highlighted.
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
TLDR
A synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma and, on the basis of immunologic assays, 91% of patients could be successfully immunized with this peptide.
Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
TLDR
Results demonstrate that mono-specific CD8(+) T cells can effectively eliminate large established tumors before the development of antigen-loss variants when a high number of T cells is rapidly administered.
T cell homeostatic proliferation elicits effective antitumor autoimmunity.
TLDR
It is demonstrated that sublethally irradiated lymphopenic mice transfused with autologous or syngeneic T cells showed tumor growth inhibition when challenged with melanoma or colon carcinoma cells, and the antitumor response depended on homeostatic expansion of a polyclonal T cell population within lymph nodes.
Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells
TLDR
It is found that tumor growth and lethality were unchanged in mice even after adoptive transfer of large numbers of T cells specific for an MHC class I–restricted epitope of the self/tumor antigen gp100, illustrating that adoptive transferof T cells and IL-2 can augment the function of a cancer vaccine.
...
1
2
3
4
5
...